UNSPSC 51383313: Diclofenac hydroxyethylpyrrolidine

This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H11Cl2NO2.C6H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X5F8EKL9ZG, chemically known as benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, compd. with 1-pyrrolidineethanol (1:1), but more generally known as diclofenac hydroxyethylpyrrolidine, which bears US NIH Compound Identifier 114753.

European Medicines Agency schedules diclofenac hydroxyethylpyrrolidine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07092MIG. Most nations, for tariff purposes, schedule diclofenac hydroxyethylpyrrolidine under HS 29224995. SMILES: C1CCC(C(C1)CC(=O)O)NC2C(CCCC2CL)CL.C1CCN(C1)CCO.

UNSPSC 51383313 Diclofenac hydroxyethylpyrrolidine is a Commodity code that nominally identifies a specific nonsteroidal anti-inflammatory drug formulation, yet recent state and local solicitation activity under this code shows a fundamental mismatch with the code's stated scope. The three most recent opportunities posted under this code involve procurement of naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription program implementation (Texas Health and Human Services Commission), and multi-source generic pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance). None of these opportunities actually solicit diclofenac or NSAID products. The code appears to be a placeholder or miscoded assignment by issuing bodies, and state and local procurement activity under UNSPSC 51383313 does not reflect demand for the pharmaceutical specified in the code's nominal definition.

The geographic spread of activity covers Florida, Texas, and Minnesota, with the most substantive recent opportunity being a cooperative purchasing vehicle. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract includes a two-year term with a one-year renewal option and is potentially FEMA-funded. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, an exploratory market-intelligence phase designed to inform future formal solicitation strategy. The Minnesota Department of Administration's Office of State Procurement, on behalf of MMCAP, issued RFP S1070000015802 on January 20, 2026, for multi-source generic pharmaceuticals and OTC products with a proposal deadline of March 26, 2026, and contracts effective July 1, 2026, through at least June 30, 2028. The code shows limited decision relevance for vendors focused on diclofenac or narrow-spectrum pharmaceutical products; the tagged opportunities reflect broader pharmaceutical supply, emergency response, and cooperative purchasing activity that diverges significantly from the code's stated drug substance.